Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

LEO Pharma’s tralokinumab meets all primary and secondary endpoints in three pivotal trials

Atopic
Anti-interleukin-13 is in development for the treatment of moderate-to-severe atopic dermatitis.